MDT-AP-1249
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- new_clusters
- S3
- umap1_2d
- -0.817628641
- umap2_2d
- -7.297946212
- umap1_3d
- -2.91741437
- umap2_3d
- -2.982987998
- umap3_3d
- 6.186187189
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.530
- E2F_TARGETS+0.490
- MTORC1_SIGNALING+0.470
- G2M_CHECKPOINT+0.430
- MYC_TARGETS_V2+0.410
- OXIDATIVE_PHOSPHORYLATION+0.380
- CHOLESTEROL_HOMEOSTASIS+0.350
- HEDGEHOG_SIGNALING+0.330
- ANGIOGENESIS+0.270
- UNFOLDED_PROTEIN_RESPONSE+0.270
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.240
- INTERFERON_GAMMA_RESPONSE-0.240
- WNT_BETA_CATENIN_SIGNALING-0.220
- KRAS_SIGNALING_DN-0.160
- HEME_METABOLISM-0.140
- BILE_ACID_METABOLISM-0.120
- INFLAMMATORY_RESPONSE-0.100
- UV_RESPONSE_DN-0.100
- XENOBIOTIC_METABOLISM-0.090
- IL6_JAK_STAT3_SIGNALING-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0322 | Med | Medulloblastoma | 0.863 |
| 2 | SRR10900569 | — | — | 0.858 |
| 3 | SRR15030865 | — | — | 0.857 |
| 4 | 56218_S133 | — | cohortSQ1 | 0.838 |
| 5 | TCGA-B6-A0IK-01A-12R-A056-07 | — | C | 0.837 |
| 6 | 5ca9ac39-e175-4890-ba6e-9ff4709d3f37 | — | — | 0.827 |
| 7 | AUR-AFR3-TTP1-A-2-1-R-A743-41 | — | C | 0.821 |
| 8 | TCGA-52-7810-01A-11R-2125-07 | — | cohortSQ1 | 0.816 |
| 9 | MNG883 | — | — | 0.814 |
| 10 | MNG432 | — | — | 0.813 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.530 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.470 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.430 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.380 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.350 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.330 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.270 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.220 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.210 | Inavolisib | — uncovered |
| HYPOXIA | 0.190 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.180 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.140 | Inavolisib | — uncovered |